The Follow-Up Problem in Psilocybin-Assisted Therapy: Integration, Aftercare, and the Missing Standard
Cacho Ernesto
Zenodo (CERN European Organization for Nuclear Research) October 14, 2026 preprint DOI: 10.5281/zenodo.23376467 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary |
|---|---|
| Topics | Psilocybin |
| Key points | Argues that integration, aftercare, and long-term follow-up in psilocybin-assisted therapy remain poorly defined compared with short-term clinical outcome measurement, and identifies gaps and opportunities in moving these practices from trials to real-world implementation in Oregon and Colorado. |
Abstract
As psilocybin-assisted therapy becomes increasingly standardized in measuring short-term clinical outcomes, the processes that follow the psychedelic experience remain far less defined. This paper examines integration, aftercare, and long-term follow-up from clinical trials to real-world implementation in Oregon and Colorado, identifying critical gaps and opportunities to better understand, evaluate, and support sustained change.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Argues that integration, aftercare, and long-term follow-up in psilocybin-assisted therapy remain poorly defined compared with short-term outcome measurement.
Synthesized